Monoclonal antibody CA208-cytorhodin-S conjugate

Drug Profile

Monoclonal antibody CA208-cytorhodin-S conjugate

Alternative Names: Cyt-S-CA208

Latest Information Update: 29 May 1997

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aventis Japan
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 29 May 1997 Changed drug development phase to discontinued (preclinical)
  • 29 May 1997 Discontinued-Preclinical for Cancer in Japan (Unknown route)
  • 22 May 1997 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top